Consortium formed for biomedical R&D

This as niche players with narrow range of services are said to be put at a disadvantage when competing with larger providers.

According to IE Singapore, the consortium will provide complete services from validation of biological target, lead candidate identification, pre-clinical research to clinical trials. The consortium also offers the flexibility to provide stand-alone services based on client needs.

It is made up of seven Singapore-based companies, namely anchor company Singapore Clinical Research Institute (SCRI) and alliance companies Dx Assays Pte Ltd, Experimental Therapeutics Centre (ETC), Innoheart Pte Ltd, Maccine Pte Ltd, MerLion Pharmaceuticals Pte Ltd and PWG Genetics Pte Ltd.

Professor Sam Lim, Chief Operating Officer, SCRI, said, “The Singapore Biomedical R&D Consortium’s companies being small and efficiently run, offer benefits of speed and flexibility. As a consortium, they provide depth of services from early product development to preclinical to late phase clinical research to the global industry partners who are looking to invest in Asia. These benefits can significantly reduce the burden, both financially and logistically, and fast-track the process of identifying and evaluating the right partners at each research phase.”